Core Viewpoint - Watson Bio (300142.SZ) has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, aiming for a target size of 1 billion yuan, with the company contributing 450 million yuan as a limited partner [1] Group 1: Investment Fund Details - The fund's target size is set at 1 billion yuan [1] - Watson Bio will invest 450 million yuan of its own funds as a limited partner [1] - The fund will focus on various investment areas including synthetic biology, life and health, biological agriculture, bioenergy, biomaterials, technology platform enterprises, and high-throughput equipment [1] Group 2: Investment Areas - Investment areas include synthetic biology such as enzyme preparations, amino acids, and probiotics [1] - Life and health investments will cover plant extracts, recombinant collagen, sweeteners, and protein drugs [1] - Biological agriculture will focus on feed protein, micro-ecological preparations, animal vaccines, and biological nitrogen fixation [1] - Bioenergy investments will include bioethanol and biodiesel [1] - Biomaterials will focus on PLA, PHA, and PDO [1] - The fund will also target technology platform enterprises like strain development and AI protein design [1] - High-throughput equipment investments will include microfluidic devices and gene sequencing equipment [1]

Group 1 - Watson Bio announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners [1] - The target scale of the fund is 1 billion yuan, with Watson Bio contributing 450 million yuan as a limited partner [1] - The fund will primarily invest in the synthetic biology manufacturing industry, including sectors such as synthetic biology, health and wellness, bio-agriculture, bio-energy, bio-materials, and technology platform enterprises [1]

Core Viewpoint - Liaoning Chengda Co., Ltd. plans to establish a biopharmaceutical investment fund in collaboration with its subsidiaries to enhance its competitiveness and capitalize on market opportunities in the healthcare sector [7][11][38]. Group 1: Investment Fund Establishment - The company intends to set up a biopharmaceutical industry investment fund with a total scale not exceeding 1 billion yuan, with an initial scale of 502 million yuan [7][11]. - The fund will focus on the life and health sector, particularly in areas such as innovative drugs, vaccines, and medical services [18][38]. - The fund's structure includes contributions from various subsidiaries, with Liaoning Chengda contributing 100 million yuan, representing approximately 19.92% of the initial fund size [8][11]. Group 2: Investment Strategy and Management - The fund will be managed by Chengda Coastal Industry (Dalian) Fund Management Co., Ltd., which is a wholly-owned subsidiary of the company [14][22]. - The investment strategy includes direct investments in high-quality projects and potential collaborations with other professional investors [18][19]. - The fund aims to achieve returns through strategic investments and timely exits from projects [19][20]. Group 3: Subsidiary Establishment - Liaoning Chengda's subsidiary, Chengda Biological Co., Ltd., plans to establish a wholly-owned subsidiary named Chengda Biological Innovation Pharmaceutical Co., Ltd. with a registered capital of 1 billion yuan [42][44]. - The investment will focus on innovative drug research and development, project acquisitions, and building a professional operational system [44][50]. - This move is part of the company's strategy to diversify its business and enhance its resilience against market fluctuations [50][52].

Core Viewpoint - Liaoning Chengda (600739.SH) plans to establish a biopharmaceutical investment fund to enhance its competitiveness and seize market opportunities, with a total fund size not exceeding 100 million yuan, and an initial size of 50.2 million yuan [1][2] Group 1: Fund Structure and Contributions - The fund will be managed by Chengda Coastal as the general partner, contributing 1 million yuan, which accounts for 0.1992% of the initial fund size [1] - Shenzhen Chengda Biotech will also act as a general partner, contributing 1 million yuan, representing 0.1992% of the initial fund size [1] - Liaoning Chengda will contribute 10 million yuan as a limited partner, making up 19.9203% of the initial fund size [1] - Chengda Biotech will contribute 40 million yuan as a limited partner, accounting for 79.6813% of the initial fund size [1] Group 2: Fund Investment Focus and Future Plans - The fund will focus on the life and health industry during its investment period, with plans to raise the total contribution to 100 million yuan within three years [2] - Shenzhen Chengda Biotech and Chengda Medical plan to increase their investment in Gene Qiming, with Shenzhen Chengda Biotech contributing 40 million yuan and Chengda Medical contributing 10 million yuan [2] - After the fund is legally established, it will acquire all shares of Gene Qiming held by Shenzhen Chengda Biotech and Chengda Medical, allowing the company to indirectly enjoy related rights through the fund [2]